Study Findings: Cancer Can Begin in Sudden Catastrophic Event

Article

A new study finds that cancer cells, conventionally thought to develop only over long periods of time can begin in a single event, accounting for the development of 2% to 3% of all cancers, and up to 25% of bone cancers.

A study in the January 7, 2011 issue of the journal Cell finds that cancer cells, conventionally thought to develop exclusively over longer periods of time can also begin in a single event, "whereby tens to hundreds of genomic rearrangements occur in a one-off cellular crisis."

[[{"type":"media","view_mode":"media_crop","fid":"21813","attributes":{"alt":"","class":"media-image media-image-right","id":"media_crop_6289479932820","media_crop_h":"239","media_crop_image_style":"-1","media_crop_instance":"1551","media_crop_rotate":"0","media_crop_scale_h":"188","media_crop_scale_w":"164","media_crop_w":"209","media_crop_x":"60","media_crop_y":"13","style":"float: right;","title":"","typeof":"foaf:Image"}}]]During the event, the chromosome shatters into tens to hundreds of pieces, parts of which are patched back together, the regenerative functions of the cell creating a new genomic structure based on this incomplete DNA. The authors, led by Philip J. Stephens of the Sanger Institute in England, found that one or more cancer-causing lesions can occur during this process.

The causal factors are not known, but some possibilities include ionizing radiation, "well-known to induce dsDNA breaks," or, because most examples of this occurrence involve regions extending to the telomeres, the damage could be a result of the "breakage-fusion-bridge cycle associated with telomere attrition."

Cancer formation could be related to copy number changes, with the new structure omitting tumor suppressor genes or containing an "increased copy number (amplification) of genes promoting malignant cellular processes."

The study reports that this episode, termed "chromothripsis" by the authors, accounts for 2% to 3% of all cancers across all tumor types, and that evidence of these events are particularly prevalent in bone cancers (up to 25%).

Twenty patients with bone cancers-9 with osteosarcoma and 11 with chordoma-were screened to detect rearrangement. Five were shown to have cells which contained the hallmarks of chromothripsis.

To read the complete article click here.

Recent Videos
9 Experts are featured in this series.
9 Experts are featured in this series.
Further optimizing a PROTAC that targets MDM2 may lead to human clinical trials among patients with cancer harboring p53 mutations.
As patients are nearing the end of life, different management strategies, such as opioids, may be needed to help mitigate pain or fatigue.
Kelley A. Rone, DNP, RN, AGNP-c, highlights the importance of having end-of-life discussions early in a patient’s cancer treatment course.
Patients treated with BCMA-directed immunotherapies for myeloma may experience susceptibility to severe infections following treatment.
4 KOLs are featured in this series.
4 KOLs are featured in this series.
4 KOLs are featured in this series.
Related Content